But while there may be a need for remedial FCC action--in the relatively rare case when there may be a proven market failure--any such action should be targeted narrowly to redress demonstrable consumer harms.
Until 2002, Biogen had the MS market to itself because of a law that grants a temporary monopoly to medicines forrare ailments, known in biotech as orphan diseases.